Authorised Therapeutic use (Phase IV) Mpox infection

Vaccination to prevent Mpox Infection (MPOX-VAX Study)

EU CTIS ID: 2023-507881-19-00

What this study is testing

Primary To assess the rate of change of (durability) of, and factors associated with, MVA-specific antibodies after at W48 post vaccination with MVA

  • Therapeutic use (Phase IV)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • Be ≥ 18 years old
  • ● Understand the study procedures, be able to comply with the procedures, and voluntarily agree to participate by giving written, informed consent for the trial
  • ● Eligible for 1 or 2 doses of MVA for Mpox prevention as per NIAC guidelines OR have received first dose of MVA <28 days previously for Mpox prevention

You likely can't join if

  • Unable or unwilling to given informed consent
  • ● Have a contraindication to MVA vaccination
  • ● Have a documented, pre-existing allergy to any component of the vaccine
  • ● Have a clinical and/or laboratory diagnosis of Mpox prior to recruitment
  • ● Pregnant or breastfeeding women

The study team makes the final eligibility decision.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.